139 related articles for article (PubMed ID: 18501601)
1. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
Lohar MV; Mundada R; Bhonde M; Padgaonkar A; Deore V; Yewalkar N; Bhatia D; Rathos M; Joshi K; Vishwakarma RA; Kumar S
Bioorg Med Chem Lett; 2008 Jun; 18(12):3603-6. PubMed ID: 18501601
[TBL] [Abstract][Full Text] [Related]
2. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.
Sun HL; Liu YN; Huang YT; Pan SL; Huang DY; Guh JH; Lee FY; Kuo SC; Teng CM
Oncogene; 2007 Jun; 26(27):3941-51. PubMed ID: 17213816
[TBL] [Abstract][Full Text] [Related]
3. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
García-Maceira P; Mateo J
Oncogene; 2009 Jan; 28(3):313-24. PubMed ID: 18978810
[TBL] [Abstract][Full Text] [Related]
4. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
Jin X; Jin HR; Lee D; Lee JH; Kim SK; Lee JJ
Eur J Pharmacol; 2008 Sep; 592(1-3):41-7. PubMed ID: 18639543
[TBL] [Abstract][Full Text] [Related]
5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
6. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Granville CA; Memmott RM; Gills JJ; Dennis PA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
[TBL] [Abstract][Full Text] [Related]
7. Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells--new insights for anti-tumor treatments.
Martinive P; Defresne F; Quaghebeur E; Daneau G; Crokart N; Grégoire V; Gallez B; Dessy C; Feron O
FEBS J; 2009 Jan; 276(2):509-18. PubMed ID: 19077164
[TBL] [Abstract][Full Text] [Related]
8. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
9. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
10. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway.
Dayan F; Bilton RL; Laferrière J; Trottier E; Roux D; Pouyssegur J; Mazure NM
J Cell Physiol; 2009 Jan; 218(1):167-74. PubMed ID: 18781596
[TBL] [Abstract][Full Text] [Related]
11. A potential mechanism for short time exposure to hypoxia-induced DNA synthesis in primary cultured chicken hepatocytes: Correlation between Ca(2+)/PKC/MAPKs and PI3K/Akt/mTOR.
Lee SH; Lee MY; Lee JH; Han HJ
J Cell Biochem; 2008 Aug; 104(5):1598-611. PubMed ID: 18646054
[TBL] [Abstract][Full Text] [Related]
12. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.
Stauffer F; Maira SM; Furet P; García-Echeverría C
Bioorg Med Chem Lett; 2008 Feb; 18(3):1027-30. PubMed ID: 18248814
[TBL] [Abstract][Full Text] [Related]
13. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway.
Won MS; Im N; Park S; Boovanahalli SK; Jin Y; Jin X; Chung KS; Kang M; Lee K; Park SK; Kim HM; Kwon BM; Lee JJ; Lee K
Biochem Biophys Res Commun; 2009 Jul; 385(1):16-21. PubMed ID: 19433063
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
[TBL] [Abstract][Full Text] [Related]
15. RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR.
Liu Z; Yuan Q; Zhang X; Xiong C; Xue P; Ruan J
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1633-40. PubMed ID: 22565593
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
[TBL] [Abstract][Full Text] [Related]
17. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells.
Choi UJ; Jee BK; Lim Y; Lee KH
Cell Biochem Funct; 2009 Jan; 27(1):40-7. PubMed ID: 19107873
[TBL] [Abstract][Full Text] [Related]
18. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
20. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
